Pharmaron Holdings Limited has completed its acquisition of Bridge Laboratories China. Both Pharmaron, which is headquartered in California, and Bridge have laboratory facilities in Beijing. Pharmaron said the acquisition would “extend” the range of services it offers. Bridge provided the first western standard GLP-compliant preclinical toxicology services in China. In August 2008, data from Bridge’s animal studies was accepted by the FDA as part of an IND filing. Terms of the Pharmaron-Bridge transaction were not disclosed. More details...